Zhaoke Ophthalmology Ltd. has announced that the National Medical Products Administration (NMPA) of China has accepted its Biologics License Application $(BLA.AU)$ for TAB014, a treatment for wet age-related macular degeneration (wAMD). This marks the first submission of a bevacizumab-based antibody for wAMD in China. The application is supported by successful Phase III clinical trial results, which demonstrated the efficacy of TAB014 in improving best corrected visual acuity compared to Lucentis®. The trial was a randomized, double-blind, non-inferiority study. Zhaoke Ophthalmology Ltd. has exclusive rights over the development and commercialization of TAB014 in China, Hong Kong, and Macau, while TOT BIOPHARM Co., Ltd. will handle manufacturing. The approval process underscores Zhaoke's commitment to advancing ophthalmic treatments in the region.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.